Kamedis to enter Chinese skin care market

7 January 2015

Israeli pharma company Kamedis has announced that it will enter the Chinese skin care market this year.

The company was established in 1998 by three traditional Chinese medicine practitioners and develops products which support the body’s natural healing abilities while providing soothing relief and improving skin appearance.

Nadav Sade, Kamedis executive vice president, said: “We are looking to establish a strategic partnership with one of the large Chinese dermo-cosmetics players. Our products are supported by clinical trials and are based on the TCM approach. Hence, we are probably the only TCM Chinese based dermo-cosmetic brand that is proven clinically to treat skin disorders."

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

More ones to watch >